A three-year clinical trial funded by the National Institutes of Health and Food Allergy Research and Education (FARE) has shown that the sublingual immunotherapy, or SLIT, is safe in peanut-allergic children ages 1 to 4, with a greater likelihood of desensitization and remission the earlier the treatment began. Led by Edwin Kim, MD, associate professor